AZ Continues To Buy Pipeline With $100M Rigel Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.
You may also be interested in...
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.
Fostamatinib Skates Through OSKIRA-1 With Mixed Results
AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed another. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.
Fostamatinib Skates Through OSKIRA-1 With Mixed Results
AstraZeneca/Rigel’s oral SYK inhibitor fostamatinib met a key primary endpoint in the first of three rheumatoid arthritis Phase III studies, but missed the other. Investors and analysts are underwhelmed with the efficacy results, although President and COO Raul Rodriguez advises holding on for the other Phase III trials before passing judgment.